68Ga-RM2

DRUG4 trials

Sponsors

Andrei Iagaru, Lightpoint Medical Limited, IRCCS San Raffaele

Conditions

Breast CancerProstate AdenocarcinomaProstate Cancer

Phase 2

68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer

CompletedNCT02624518

Andrei IagaruProstate Adenocarcinoma

Start: 2015-11-16End: 2022-11-30Updated: 2023-04-10

PET/MR for Prostate Cancer Restaging: a Phase II Prospective Monocentric Study

CompletedNCT05806853

IRCCS San RaffaeleProstate Cancer

Start: 2020-06-03End: 2022-10-05Updated: 2023-04-10

PET/MRI to Stage Prostate Cancer Patients

RecruitingNCT06484361

IRCCS San RaffaeleProstate Cancer

Start: 2020-09-09End: 2025-09-30Target: 50Updated: 2024-07-03

Phase 3

The LightPath® and 68Ga-RM2 in Breast Cancer Study

Lightpoint Medical LimitedBreast Cancer

Start: 2018-11-30End: 2023-11-30Target: 80Updated: 2018-11-06

Related Papers

<sup>68</sup>Ga-RM2 PET-MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: a single-centre, single-arm, phase 2/3 imaging trial.

2024-02-2614 citations

Modified PROMISE criteria for standardized interpretation of gastrin-releasing peptide receptor (GRPR)-targeted PET.

2023-08-097 citations

Reduced Acquisition Time per Bed Position for PET/MRI Using <sup>68</sup>Ga-RM2 or <sup>68</sup>Ga-PSMA-11 in Patients With Prostate Cancer: A Retrospective Analysis

American Journal of Roentgenology2021-12-085 citations

A prospective study of <sup>68</sup>Ga-RM2 PET/MRI in patients with biochemically recurrent prostate cancer and negative conventional imaging.

Journal of Clinical Oncology2020-05-201 citations